Uday R Popat, M.D.
Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine
About Dr. Popat
Dr. Uday Popat graduated from the Lokmanya Tilak Municipal Medical College in Bombay, India. He completed the residency and fellowship programs at institutions in the United Kingdom, India and the United States including Baylor College of Medicine and The University of Texas MD Anderson Cancer Center. He is currently Professor of Medicine in the department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center.
Present Title & Affiliation
Primary Appointment
Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Myelofibrosis: Reduced intensity allogeneic transplantation(SCT) for myelofibrosis: This is a novel study, first protocol in this disease at MDACC and the largest single center study, which is still accruing patients. Our preliminary results are encouraging. If these hold over a period of time, this should become standard of care and establish allogeneic transplant as a viable, curative therapy. In a separate study we showed that long term remission was possible in patients with AML post MF after SCT. This finding has not been previously reported.
Multiple Sclerosis: My previous study and current ongoing study at MDACC will go some way in establishing a role for autologous transplantation in this disease. Our study on allogeneic transplantation for patients with ALS was novel and although negative for clinical endpoints did show significant trafficking of donor hematopoietic stem cells to diseased areas in central nervous system.
Imapct of comorbidities on SCT: To identify patients most suitable for allo transplant and to identify the most suitable transplant strategy for patients with comorbidities.
Risk factors predicting stem cell mobilization failure.Education & Training
Degree-Granting Education
| 2016 | Rice University, Houston, TX, USA, MBA, Business Administration |
| 2003 | Royal College of Pathologists, London, GBR, FRCPath, Hematology |
| 1995 | Royal College of Pathologists, London, GBR, MRCPath, Hematology |
| 1994 | Royal College of Pathologists, London, GBR, Dip RCPath, Hematology |
| 1991 | Royal College of Physicians, London, GBR, MRCP, Internal Medicine |
| 1988 | University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bomabay, IND, MD, Internal Medicine |
| 1983 | University of Bombay, Lokmanya Tilak Municipal Medical College & Hospital, Bombay, IND, MB, BS, Med School |
Postgraduate Training
| 1997-1999 | Residency, Internal Medicine, Baylor College of Medicine, Houston, TX |
| 1996-1997 | Fellowship, Hematology and Medical Oncology, Baylor College of Medicine, Houston, TX |
| 1995-1996 | Fellowship, Bone Marrow Transplant, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 1994-1995 | Fellowship, Bone Marrow Transplant, Royal Free Hospital and School of Medicine University of London, London |
| 1983-1988 | Internship and Residency, Internal Medicine, Lokmanya Tilak Municipal Medical College and General Hospital, University of Bombay, Bombay |
Board Certifications
| 2001 | American Board of Internal Medicine, Medical Oncology |
| 2001 | American Board of Internal Medicine, Hematology |
| 2000 | American Board of Internal Medicine, Internal Medicine |
Experience & Service
Academic Appointments
Associate Professor, Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2011
Administrative Appointments/Responsibilities
Associate Program Director, Department of Stem Cell Transplant Fellowship, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - Present
Institutional Committee Activities
Member, Search committee for Neuro onc, 2019 - Present
Member, Operative task force 6, 2019 - Present
Member, Urgent care task force, 2019 - Present
Member, Cost accounting committee, 2019 - Present
Member, Executive Committee of Medical Staff, 2018 - Present
Member, TMC 2 Taskforce, 2017 - Present
Member, PRS Faculty Compensation & Benefit Advisory Committee, 2017 - Present
Member, Operational Priority 2 Financial Sustainability, 2017 - Present
Member, Executive Institutional Compliance Committee, 2017 - 2018
Member, Faculty Senate Executive Committee, 2015 - 2017
Member, Credentials Committee of the Medical Staff, 2015 - Present
Quality Officer, Quality Officer for Stem Cell Transplantation and Cellular Therapy, 2011 - Present
Member, Clinical Research Committee - CRC 2, 2011 - 2015
Alternate Member, Credentials Committee of the Medical Staff, 2011 - 2015
Member, Computerized Provider Order Entry (CPOE) Steering Committee, 2010 - Present
Member, Faculty Senate, 2010 - 2018
Member, Infection Control Committee, 2008 - 2013
Member, Infection Control Core Group, 2008 - 2013
Honors & Awards
| 2009 | Best Doctors in America, Best Doctors, Inc |
Selected Publications
Peer-Reviewed Articles
- Akpek G, Pasquini MC, Logan B, Agovi MA, Lazarus HM, Marks DI, Bornhaeüser M, Ringdén O, Maziarz RT, Gupta V, Popat U, Maharaj D, Bolwell BJ, Rizzo JD, Ballen KK, Cooke KR, McCarthy PL, Ho VT. Effects of spleen status on early outcomes after hematopoietic cell transplantation. Bone Marrow Transplant 48(6):825-31, 2013. e-Pub 2012. PMID: 23222382.
- Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-7, 2013. e-Pub 2012. PMID: 23128322.
- Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
- Oran B, Popat U, Rondon G, Ravandi F, Garcia-Manero G, Abruzzo L, Andersson BS, Bashir Q, Chen J, Kebriaei P, Khouri IF, Koca E, Qazilbash MH, Champlin R, de Lima M. Significance of Persistent Cytogenetic Abnormalities on Myeloablative Allogeneic Stem Cell Transplantation in First Complete Remission. Biol Blood Marrow Transplant 19(2):214-20, 2013. e-Pub 2012. PMID: 22982533.
- de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. PMID: 23234514.
- Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2012. e-Pub 2011. PMID: 21423123.
- Hou P, Popat UR, Lindsay RJ, Jackson EF, Choi H. A practical approach for a wide range of liver iron quantitation using a magnetic resonance imaging technique. Radiol Res Pract 2012:207391, 2012. e-Pub 2012. PMID: 23365743.
- Joseph RW, Alousi A, Konda B, Komanduri K, Neumann J, Trevino C, Stolar K, Qazilbash M, Hosing C, Kebriaei P, Couriel DR, Champlin RE, Saliba R, Popat U. High incidence of vitamin D deficiency in patients undergoing allogeneic stem cell transplantation. Am J Hematol 86(11):954-6, 2011. e-Pub 2011. PMID: 21948087.
- Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS, Hosing CM, Verstovsek S, Champlin RE, Popat U. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 16(4):555-9, 2010. e-Pub 2010. PMID: 20005966.
- Parmar S, Del Lima M, Zou Y, Patah PA, Liu P, Cano P, Rondon G, Pesoa S, de Padua Silva L, Qazilbash MH, Hosing C, Popat U, Kebriaei P, Shpall EJ, Giralt S, Champlin RE, Stastny P, Fernandez-Vina M. Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease. Blood 114(14):2884-7, 2009. e-Pub 2009. PMID: 19654407.
- Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of Filgrastim-Induced Stem Cell Mobilization after Prior Lenalidomide in Patients with Multiple Myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
- Hosing C, Saliba RM, Ahlawat S, Körbling M, Kebriaei P, Alousi A, De Lima M, Okoroji JG, McMannis J, Qazilbash M, Anderlini P, Giralt S, Champlin RE, Khouri I, Popat U. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 84(6):335-7, 2009. e-Pub 2009. PMID: 19384931.
- Champlin R, de Lima M, Kebriaei P, Rondon G, Fisher T, Jabbour E, Cortés JE, Kantarjian H, Anderlini P, Alousi A, Hosing C, Shpall E, Popat U, Qazilbash M, Andersson B, Giralt S. Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era. Clin Lymphoma Myeloma 9(3):S261-5, 2009. PMID: 19778850.
- Appel SH, Engelhardt JI, Henkel JS, Siklos L, Beers DR, Yen AA, Simpson EP, Luo Y, Carrum G, Heslop HE, Brenner MK, Popat U. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 71(17):1326-34, 2008. PMID: 18936424.
- Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA, Champlin RE, Ciurea SE, Manshouri T, Pierce SM, Kantarjian HM, Verstovsek S. The natural history and treatment outcome of blast phase BCR-ABL negative myeloproliferative neoplasms. Blood 112(5):1628-37, 2008. e-Pub 2008. PMID: 18566326.
- Nash RA, Stuve O, Bowen JD, Frohman EM, Griffith LM, Hutton GJ, Kraft GH, Popat U, Racke MK, Muraro PA. Autologous HSCT for advanced MS: is the glass half-empty or really half-full?. Brain 131(Pt 2):e89, 2008. e-Pub 2007. PMID: 17908695.
- Samuelson SJ, Popat U, Prchal JT. Marrow fibrosis does not account for circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Haematologica 92(4 e47):ELT02, 2007. PMID: 17405759.
- Popat U, Frost A, Liu E, Guan Y, Durette A, Reddy V, Prchal JT. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 107(9):3486-3488, 2006. e-Pub 2006. PMID: 16418333.
- Popat U, Heslop HE, Durett A, May R, Krance RA, Brenner MK, Carrum G. Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplant 37(6):547-52, 2006. PMID: 16462757.
- Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, Gee AP, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. Blood 107(4):1332-1341, 2006. e-Pub 2005. PMID: 16249392.
- Lamba R, Carrum G, Myers GD, Bollard CM, Krance RA, Heslop HE, Brenner MK, Popat U. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with Alemtuzumab. Bone Marrow Transplant 36(9):797-802, 2005. PMID: 16151431.
- Popat U, Frost A, Liu E, May R, Bag R, Reddy V, Prchal JT. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med 143(6):466-467, 2005. PMID: 16172450.
- Burt RK, Cohen B, Rose J, Petersen F, Oyama Y, Stefoski D, Katsamakis G, Carrier E, Kozak T, Muraro PA, Martin R, Hintzen R, Slavin S, Karussis D, Haggiag S, Voltarelli JC, Ellison GW, Jovanovic B, Popat U, McGuirk J, Statkute L, Verda L, Haas J, Arnold R. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 62(6):860-4, 2005. PMID: 15956156.
Invited Articles
- Popat U, Carrum G, Heslop HE. Haemopoietic stem cell transplantation for acute lymphoblastic leukaemia. Cancer Treat Rev 29(1):3-10, 2003. PMID: 12633575.
Book Chapters
- Rice L, Popat U. Non-Hodgkin's Lymphoma. In: Conn's Current Therapy 2008. Saunders-Elsevier: United Kingdom, 458-461, 2008.
- Popat U, Giralt S. Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia. In: Contemporary Hematology, Stem Cell Transplantation for Hematoligic and other Disorders. Humana Press: Totowa, NJ, 2008.
- Popat U, Giralt S. Hematopoietic cell transplantation for chronic myeloid leukemia and myelofibrosis. In: Chronic Myeloproliferative Disorders. Informa Press, 2008.
- Fanale M, Dabaja B, Anderlini P, Popat U. 60 Years of Survival Outcomes at The University of Texas M.D. Anderson Cancer Center. In: The MD Anderson Manual of Medical Oncology. Springer Science.
Grant & Contract Support
| Title: | Phase I Evaluation of the Safety and Efficacy of TXA127 (Angiotensin 17) to Enhance Engraftment in Adults Undergoing Double Cord Blood Transplantation |
| Funding Source: | US Biotest, Inc |
| Role: | Principal Investigator |
| Title: | Allogeneic stem cell transplantation for myelofibrosis using reduced intensity busulfan and fludarabine conditioning |
| Funding Source: | Otsuka Pharmaceutical Company Ltd |
| Role: | Principal Investigator |
| Title: | High dose immunosuppression and autologous transplantation for multiple sclerosis (HALT MS) study |
| Funding Source: | NIH/NCI |
| Role: | Principal Investigator-MDACC |
| Title: | Eltrombopag for post transplant thrombocytopenia |
| Funding Source: | GlaxoSmithKline |
| Role: | Principal Investigator |